Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) was downgraded by investment analysts at Evercore from an “outperform” rating to an “in-line” rating in a report released on Thursday, Briefing.com reports. They presently have a $16.00 target price on the biopharmaceutical company’s stock. Evercore’s price objective would indicate a potential downside of 39.69% from the stock’s current price.
Several other research firms have also commented on RARE. Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th. Cantor Fitzgerald boosted their target price on Ultragenyx Pharmaceutical from $96.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Robert W. Baird downgraded Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and set a $16.00 price target for the company. in a report on Thursday. Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Citigroup increased their price objective on shares of Ultragenyx Pharmaceutical from $45.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $51.53.
Read Our Latest Analysis on Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Trading Up 2.8%
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The company had revenue of $214.00 million for the quarter, compared to the consensus estimate of $183.08 million. During the same quarter last year, the company earned ($1.17) earnings per share. The firm’s revenue for the quarter was up 28.5% compared to the same quarter last year. On average, equities research analysts forecast that Ultragenyx Pharmaceutical will post -3.97 EPS for the current year.
Insider Transactions at Ultragenyx Pharmaceutical
In related news, Director Corazon (Corsee) D. Sanders sold 2,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $25.05, for a total transaction of $50,100.00. Following the completion of the sale, the director owned 21,095 shares of the company’s stock, valued at $528,429.75. The trade was a 8.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Karah Herdman Parschauer sold 1,899 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the completion of the transaction, the executive vice president owned 94,462 shares in the company, valued at approximately $2,325,654.44. This trade represents a 1.97% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 5.20% of the company’s stock.
Institutional Investors Weigh In On Ultragenyx Pharmaceutical
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Ultragenyx Pharmaceutical by 2.0% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 26,932 shares of the biopharmaceutical company’s stock valued at $817,000 after buying an additional 534 shares during the period. Van ECK Associates Corp boosted its position in Ultragenyx Pharmaceutical by 26.1% in the 3rd quarter. Van ECK Associates Corp now owns 2,650 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 549 shares in the last quarter. Tidal Investments LLC grew its stake in shares of Ultragenyx Pharmaceutical by 4.7% during the 2nd quarter. Tidal Investments LLC now owns 12,591 shares of the biopharmaceutical company’s stock worth $458,000 after purchasing an additional 564 shares during the period. Rafferty Asset Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 0.4% during the 4th quarter. Rafferty Asset Management LLC now owns 157,061 shares of the biopharmaceutical company’s stock worth $3,612,000 after purchasing an additional 577 shares during the period. Finally, Smartleaf Asset Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 43.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,489 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 751 shares during the period. 97.67% of the stock is owned by institutional investors and hedge funds.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.
The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.
Featured Stories
- Five stocks we like better than Ultragenyx Pharmaceutical
- Enova’s Earnings Surge Meets a Valuation Test
- SLB’s Kelvion Deal Could Change How Investors Value the Oilfield Giant
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
-online-lending--digital-banking-etf-logo-1200x675.png){kind=logo}
